Belotero Volume (+) Lidocaine Dermal Filler
Merz North America, Inc. · Decision date Sep 10, 2026
What did the FDA decide?
The FDA record P250020/S005 shows an OK30 decision dated 2026-09-10 for a 30-Day Notice submitted by Merz North America, Inc. The stated purpose is approval for requalification of the cleanroom and controlled manufacturing areas at Merz Aesthetics GmbH (FEI 3036164410), with Belotero Volume (+) Lidocaine Dermal Filler listed as the affected device. The record categorizes the supplement reason as Process Change - Manufacturer/Sterilizer/Packager/Supplier.
The S005 identifier places this supplement under PMA P250020, but the source statement describes a facility-level requalification of cleanroom and controlled manufacturing areas, not an original PMA or a new approval of the whole system. The fields do not specify which cleanroom parameters were requalified, what testing supported the requalification, or any clinical data; that information is absent from the supplied text. The OK30 order reflects the reported regulatory purpose and does not itself establish safety or clinical effectiveness.
The device category is listed as implant, dermal, for aesthetic use, with product code LMH and specialties General and Plastic Surgery.
FDA approval order statement
Approval for requalification of the cleanroom and controlled manufacturing areas at Merz Aesthetics GmbH facility (FEI 3036164410) affecting Belotero Volume (+) Lidocaine Dermal Filler
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Sep 10, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P250020/S005
- Regulatory pathway
- PMA supplement
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- Decision code
- OK30
- Decision date
- Sep 10, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Implant, dermal, for aesthetic use.
- Applicant
- Merz North America, Inc.
- Product code
- LMH
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P250020. Subsequent supplements may change the device or its indications.
FDA decision timeline
P250020 · Original PMA
Belotero Volume (+) Lidocaine
P250020/S005 received
Application receipt date recorded by FDA.
P250020/S005 · FDA decision
30-Day Notice
P250020/S004 · Related supplement
Belotero Volume (+) Lidocaine
Timeline entries are records held by MedtechLedger for P250020. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P250020
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Merz North America, Inc. | PMA approval | May 19, 2026 | FDA | |
Belotero Volume (+) LidocaineP250020/S004 | Merz North America, Inc. | PMA supplement | Nov 4, 2026 | FDA |
Explore the linked device profile
Other records with product code LMH
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Juvéderm Ultra XC; Juvéderm Ultra Plus XCP050047/S106 | Allergan | PMA supplement | Nov 4, 2026 | FDA |
Belotero Intense (+) Lidocaine Dermal FillerP250016/S006 | Merz North America, Inc. | PMA supplement | Oct 21, 2026 | FDA |
| Prollenium Medical Technologies, Inc. | PMA supplement | Oct 14, 2026 | FDA | |
saypha ChiQP250021/S002 | Croma-Pharma GmbH | PMA supplement | Oct 8, 2026 | FDA |
saypha ChiQP250021/S001 | Croma-Pharma GmbH | PMA supplement | Oct 7, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Merz North America, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6501 Six Forks Rd., Raleigh, NC, 27615
Sources and methodology
- Original FDA record: P250020/S005
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records




